Tolerability Study of Investigational Agent, ARRY-142886, in Patients With Cancer - Tabular View

Tracking Information
First Received Date ^ICMJE	June 14, 2004
Last Updated Date	March 24, 2009
Start Date ^ICMJE
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00085787 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	Tolerability Study of Investigational Agent, ARRY-142886, in Patients With Cancer
Official Title ^ICMJE	A Phase I, Open-Label, Multiple Dose Study to Assess the Tolerability, Pharmacokinetics and Pharmacodynamics of ARRY-142886 Given on a Daily Oral Regime in Subjects With Advanced Solid Malignancies
Brief Summary	The purpose of this study is to assess the tolerability of ARRY-142886 in patients with advanced solid malignancies that have failed standard therapy or for whom no standard therapy exists and determine the maximum tolerated dose as defined by significant dose limiting toxicity.
Detailed Description
Study Phase	Phase I
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment, Open Label, Pharmacokinetics/Dynamics Study
Condition ^ICMJE	Cancer
Intervention ^ICMJE	Drug: ARRY-142886
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE	Inclusion Criteria: Confirmed solid tumor which is refractory to standard therapies At least 18 years old Ambulatory with ECOG status of 0-2 Life expectancy of greater than or equal to 3 months Exclusion Criteria: Brain metastases Use of investigational medication or device within 30 days Major surgery within 30 days Radiotherapy or chemotherapy within 21 days Pregnant or lactating Known positive for HIV
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT ID ^ICMJE	NCT00085787
Responsible Party
Study ID Numbers ^ICMJE	ARRY-0401
Study Sponsor ^ICMJE	Array BioPharma
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	Array BioPharma
Verification Date	March 2009
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP